A Study of AZD0486 for B-Cell Malignancies
Phase 1/2
276
about 3.1 years
18+
12 sites in MA, NC, NJ +6
About this study
Researchers are testing the safety and effectiveness of AZD0486, either alone or with other cancer drugs, in people with certain types of lymphoma. The trial will last about 1 year and involve a total of approximately 276 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take AZD0486
- 2.Take Acalabrutinib
- 3.Take Cyclophosphamide
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
acalabrutinib, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), doxorubicin (Anthracycline chemotherapy; intercalates DNA and inhibits topoisomerase II), prednisone, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), vincristine
oral (Oral Capsule), infusion, oral
Primary: Number of Participants with Adverse Events, Serious Adverse Events and Adverse Events of Special Interest, Number of Participants with Dose Limiting Toxicity (DLTs)
Secondary: Area Under the Concentration-time Curve (AUC), Clearance (CL) of surovatamig, Complete Response (CR) Rate, Duration of Response (DoR), Half Life (t1/2) of surovatamig, Maximum Observed Concentration (Cmax), Overall Response Rate (ORR), Time to Reach Maximum Concentration (tmax)
Oncology